Mohamed Elmeliegy

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 13

Top Topics

Acute Myeloid Leukemia

Multiple Myeloma

Rheumatoid Arthritis Patients

Drug Administration

Top Venues

Clinical pharmacology and therapeutics

Journal of clinical pharmacology

Clinical pharmacokinetics

CPT: pharmacometrics & systems pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Mohamed Elmeliegy, Joseph Chen, Aruna Dontabhaktuni, Allison Gaudy, Georgi I Kapitanov, Junyi Li, Sabiha R Mim, Sharad Sharma, Qin Sun, Sihem Ait-Oudhia
Dosing Strategies and Quantitative Clinical Pharmacology for Bispecific T-Cell Engagers Development in Oncology. Clinical pharmacology and therapeutics (2024)
Mohamed Elmeliegy, Joseph Chen, Aruna Dontabhaktuni, Allison Gaudy, Georgi I Kapitanov, Junyi Li, Sabiha R Mim, Sharad Sharma, Qin Sun, Sihem Ait-Oudhia
Dosing Strategies and Quantitative Clinical Pharmacology for Bispecific T-Cell Engagers Development in Oncology. Clinical pharmacology and therapeutics 116 (3) (2024)
Pooneh Soltantabar, Sheena Sharma, Diane Wang, Hoi-Kei Lon, Akos Czibere, Anne Hickmann, Mohamed Elmeliegy
Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta-Analysis. Clinical pharmacology and therapeutics 115 (6) (2024)
Pooneh Soltantabar, Sheena Sharma, Diane Wang, Hoi-Kei Lon, Akos Czibere, Anne Hickmann, Mohamed Elmeliegy
Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta-Analysis. Clinical pharmacology and therapeutics (2024)
Pooneh Soltantabar, Sheena Sharma, Diane Wang, Hoi-Kei Lon, Akos Czibere, Anne Hickmann, Mohamed Elmeliegy
Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta-Analysis. Clinical pharmacology and therapeutics 115 (6) (2024)
Pooneh Soltantabar, Ali Alhadab, Jennifer Hibma, Satrajit Roychoudhury, Diane D Wang, Carlo Bello, Mohamed Elmeliegy
Case-control matching-guided exposure-efficacy relationship for avelumab in patients with urothelial carcinoma. CPT: pharmacometrics & systems pharmacology (2023)
Archana M Agarwal, Arun A Azad, Neal D Shore, Joan Carles, Andre P Fay, Curtis Dunshee, Lawrence Ivan Karsh, Maria Luisa Paccagnella, Nicola Di Santo, Mohamed Elmeliegy, Xun Lin, Akos Czibere, Karim Fizazi
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. Future oncology (London, England) 18 (4) (2022)
Mohamed Elmeliegy, Chandrasekhar Udata, Ken Liao, Donghua Yin
Considerations on the Calculation of the Human Equivalent Dose from Toxicology Studies for Biologic Anticancer Agents. Clinical pharmacokinetics 60 (5) (2021)
Mohamed Elmeliegy, Manoli Vourvahis, Cen Guo, Diane D Wang
Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug-Drug Interaction Studies. Clinical pharmacokinetics 59 (6) (2021)
Mohamed Elmeliegy, Yanke Yu, Jennifer K Litton, Akos Czibere, Gary G Wilson, Iulia Cristina Tudor, Jenny Zheng, Diane D Wang
Exposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials. Journal of clinical pharmacology 60 (10) (2020)
Mohamed Elmeliegy, Jason Den Haese, Chetasi Talati, Meir Wetzler, William J Jusko
Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia. Cancer chemotherapy and pharmacology 86 (3) (2020)
Mohamed Elmeliegy, Derek Z Yang, Engie Salama, Kourosh Parivar, Diane D Wang
Discordance Between Child-Pugh and National Cancer Institute Classifications for Hepatic Dysfunction: Implications on Dosing Recommendations for Oncology Compounds. Journal of clinical pharmacology 61 (1) (2020)
Yanke Yu, Mohamed Elmeliegy, Jennifer K Litton, Iulia Cristina Tudor, Akos Czibere, Jenny Zheng, Diane D Wang
Talazoparib Exposure-Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA Trial. Journal of clinical pharmacology 60 (10) (2020)